Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study.
Selke Krulichová I, Selke GW, Bennie M, Hajiebrahimi M, Nyberg F, Fürst J, Garuolienė K, Poluzzi E, Slabý J, Yahni CZ, Altini M, Fantini MP, Kočí V, McTaggart S, Pontes C, Reno C, Rosa S, Pedrola MT, Udovič M, Wettermark B. Selke Krulichová I, et al. Among authors: furst j. Pharmacoepidemiol Drug Saf. 2022 Oct;31(10):1046-1055. doi: 10.1002/pds.5509. Epub 2022 Jul 18. Pharmacoepidemiol Drug Saf. 2022. PMID: 35791700 Free PMC article.
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, Brzezinska A, Bucsics A, Campbell S, Ferrario A, Finlayson AE, Fürst J, Garuoliene K, Gomes M, Gutiérrez-Ibarluzea I, Haycox A, Hviding K, Herholz H, Hoffmann M, Jan S, Jones J, Joppi R, Kalaba M, Kvalheim C, Laius O, Langner I, Lonsdale J, Lööv SÄ, Malinowska K, McCullagh L, Paterson K, Markovic-Pekovic V, Martin A, Piessnegger J, Selke G, Sermet C, Simoens S, Tulunay C, Tomek D, Vončina L, Vlahovic-Palcevski V, Wale J, Wilcock M, Wladysiuk M, van Woerkom M, Zara C, Gustafsson LL. Malmström RE, et al. Among authors: furst j. Front Pharmacol. 2013 May 14;4:39. doi: 10.3389/fphar.2013.00039. eCollection 2013. Front Pharmacol. 2013. PMID: 23717279 Free PMC article.
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Godman B, Malmström RE, Diogene E, Jayathissa S, McTaggart S, Cars T, Alvarez-Madrazo S, Baumgärtel C, Brzezinska A, Bucsics A, Campbell S, Eriksson I, Finlayson A, Fürst J, Garuoliene K, Gutiérrez-Ibarluzea I, Hviding K, Herholz H, Joppi R, Kalaba M, Laius O, Malinowska K, Pedersen HB, Markovic-Pekovic V, Piessnegger J, Selke G, Sermet C, Spillane S, Tomek D, Vončina L, Vlahović-Palčevski V, Wale J, Wladysiuk M, van Woerkom M, Zara C, Gustafsson LL. Godman B, et al. Among authors: furst j. Front Pharmacol. 2014 Jun 10;5:109. doi: 10.3389/fphar.2014.00109. eCollection 2014. Front Pharmacol. 2014. PMID: 24959145 Free PMC article. Review.
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, Bishop I, Bucsics A, Campbell S, Finlayson AE, Fürst J, Garuoliene K, Herholz H, Kalaba M, Laius O, Piessnegger J, Sermet C, Schwabe U, Vlahović-Palčevski VV, Markovic-Pekovic V, Vončina L, Malinowska K, Zara C, Gustafsson LL. Godman B, et al. Among authors: furst j. Front Pharmacol. 2014 Jun 17;5:106. doi: 10.3389/fphar.2014.00106. eCollection 2014. Front Pharmacol. 2014. PMID: 24987370 Free PMC article. Review.
Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe.
Matusewicz W, Godman B, Pedersen HB, Fürst J, Gulbinovič J, Mack A, Selke G, Timoney A, Warmińska E, Malmström RE. Matusewicz W, et al. Among authors: furst j. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755-8. doi: 10.1586/14737167.2015.1085803. Epub 2015 Sep 14. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 26368060 Free article. No abstract available.
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Ermisch M, Bucsics A, Vella Bonanno P, Arickx F, Bybau A, Bochenek T, van de Casteele M, Diogene E, Fürst J, Garuolienė K, van der Graaff M, Gulbinovič J, Haycox A, Jones J, Joppi R, Laius O, Langner I, Martin AP, Markovic-Pekovic V, McCullagh L, Magnusson E, Nilsen E, Selke G, Sermet C, Simoens S, Sauermann R, Schuurman A, Ramos R, Vlahovic-Palcevski V, Zara C, Godman B. Ermisch M, et al. Among authors: furst j. Front Pharmacol. 2016 Sep 28;7:305. doi: 10.3389/fphar.2016.00305. eCollection 2016. Front Pharmacol. 2016. PMID: 27733828 Free PMC article.
Policies for biosimilar uptake in Europe: An overview.
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S. Moorkens E, et al. Among authors: furst j. PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017. PLoS One. 2017. PMID: 29284064 Free PMC article.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S, Kurdi A, Gad M, Gulbinovič J, Timoney A, Bochenek T, Salem A, Hoxha I, Sauermann R, Massele A, Guerra AA Jr, Petrova G, Mitkova Z, Achniotou G, Laius O, Sermet C, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Oluka M, Kwon HY, Jakupi A, Kalemeera F, Fadare JO, Melien O, Pomorski M, Wladysiuk M, Marković-Peković V, Mardare I, Meshkov D, Novakovic T, Fürst J, Tomek D, Zara C, Diogene E, Meyer JC, Malmström R, Wettermark B, Matsebula Z, Campbell S, Haycox A. Godman B, et al. Among authors: furst j. Front Public Health. 2018 Dec 5;6:328. doi: 10.3389/fpubh.2018.00328. eCollection 2018. Front Public Health. 2018. PMID: 30568938 Free PMC article. Review.
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, Ermisch M, Simoens S, Hauegen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Pontes C, et al. Among authors: furst j. Appl Health Econ Health Policy. 2020 Feb;18(1):5-16. doi: 10.1007/s40258-019-00527-x. Appl Health Econ Health Policy. 2020. PMID: 31696433 Free article.
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, Stockinger S, Mörtenhuber S, Dimitrova M, Tachkov K, Vončina L, Palčevski VV, Achniotou G, Slabý J, Popelková L, Kohoutová K, Bartels D, Laius O, Martikainen JE, Selke GW, Kourafalos V, Magnússon E, Einarsdóttir R, Adams R, Joppi R, Allocati E, Jakupi A, Viksna A, Greičiūtė-Kuprijanov I, Vella Bonanno P, Suttorp V, Melien Ø, Plisko R, Mardare I, Meshkov D, Novakovic T, Fürst J, Zara C, Marković-Peković V, Grubiša N, Befrits G, Puckett R, Vulto AG. Moorkens E, et al. Among authors: furst j. Front Pharmacol. 2021 Jan 8;11:591134. doi: 10.3389/fphar.2020.591134. eCollection 2020. Front Pharmacol. 2021. PMID: 33519450 Free PMC article.
221 results